The CLL interphase fluorescence in situ hybridization (FISH) panel analysis was normal. There were no cells with CCND1-IGH fusion. No extra signals or deletions of ATM, chromosome 12, 13q, or TP53 were observed.

**SPECIFIC FISH RESULTS:**

- **CCND1/IGH:** NORMAL  
  `nuc ish 11q13(CCND1x2),14q32(IGHx2)[100]`

- **ATM:** NORMAL  
  `nuc ish 11q22.3(ATMx2)[100]`

- **12cen:** NORMAL  
  `nuc ish 12cen(D12Z3x2)[100]`

- **13q:** NORMAL  
  `nuc ish 13q14.3(DLEUx2),13q34(TFDP1x2)[100]`

- **TP53:** NORMAL  
  `nuc ish 17p13.1(TP53x2)[100]`

This analysis is limited to abnormalities detectable.
by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

REFERENCES:

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

Director Review: M. Katharine Rudd, PhD, FACMG

Comment: 01

For inquiries, the physician may contact Branch: 800−222−7566 Lab: 800−735−4087
**Interpretation:**

The CLL interphase fluorescence in situ hybridization (FISH) panel analysis was normal. There were no cells with CCND1-IGH fusion. No extra signals or deletions of ATM, chromosome 12, 13q, or TP53 were observed.

**Specific FISH Results:**

**CCND1/IGH:** NORMAL  
nuc ish 11q13(CCND1x2),14q32(IGHx2)[100]

**ATM:** NORMAL  
nuc ish 11q22.3(ATMx2)[100]

**12cen:** NORMAL  
nuc ish 12cen(D12Z3x2)[100]

**13q:** NORMAL  
nuc ish 13q14.3(DLEUx2),13q34(TFDP1x2)[100]

**TP53:** NORMAL  
nuc ish 17p13.1(TP53x2)[100]

This analysis is limited to abnormalities detectable by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

**References:**


This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
LCLS Specimen Number: 238-225-9015-0
Patient Name: SAMPLE REPORT, 510340
Date of Birth: 10/18/1956
Gender: F
Patient ID: 
Lab Number: YU16-67593   F

Account Number: 9000999
Ordering Physician: 
Specimen Type: BLOOD
Client Reference: 
Date Collected: 08/25/2016
Date Received: 08/26/2016

M. Katharine Rudd, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director
Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,
1904 TW Alexander Drive , RTP , NC , 27709-0153  (800) 345-4363
Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD. Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
This document contains private and confidential health information protected by state and federal law.
**CLL FISH Panel**

Specimen Type: BLOOD

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells Counted</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>01</td>
</tr>
<tr>
<td>Cells Analyzed</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>01</td>
</tr>
<tr>
<td>FISH Result</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>01</td>
</tr>
</tbody>
</table>

**Interpretation:**

The CLL interphase fluorescence in situ hybridization (FISH) panel analysis was positive for loss of one 13q14 signal. Results for CCND1/IGH, ATM, chromosome 12, and TP53 were normal.

Deletion of the tumor suppressor loci at 13q is a common finding in CLL. Patients with 13q deletions as the sole anomaly detected by FISH are reported to have the longest survival time.

**SPECIFIC FISH RESULTS:**

- **13q:** ABNORMAL
  - nuc ish 13q14.3(DLEUx1), 13q34(TFDP1x2) [50/100]
  - CCND1/IGH: NORMAL
    - nuc ish 11q13(CCND1x2), 14q32(IGHx2) [100]
  - ATM: NORMAL
    - nuc ish 11q22.3(ATMx2) [100]
  - 12cen: NORMAL
    - nuc ish 12cen(D12Z3x2) [100]
TP53: NORMAL

nuc ish 17p13.1(TP53x2)[100]

This analysis is limited to abnormalities detectable by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

REFERENCES:

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
Test: **CLL FISH Panel**

Cells Counted: 100/PROBE

Cells Analyzed: 100/PROBE

**FISH RESULT:** 50% OF NUCLEI POSITIVE FOR 13Q DELETION

**INTERPRETATION:** CLL RELATED CLONE DETECTED

The CLL interphase fluorescence in situ hybridization (FISH) panel analysis was positive for loss of one 13q14 signal. Results for CCND1/IGH, ATM, chromosome 12, and TP53 were normal.

Deletion of the tumor suppressor loci at 13q is a common finding in CLL. Patients with 13q deletions as the sole anomaly detected by FISH are reported to have the longest survival time.

**SPECIFIC FISH RESULTS:**

13q: ABNORMAL
   nuc ish 13q14.3(DLEUx1),13q34(TFDP1x2) [50/100]

CCND1/IGH: NORMAL
   nuc ish 11q13(CCND1x2),14q32(IGHx2) [100]

ATM: NORMAL
   nuc ish 11q22.3(ATMx2) [100]

12cen: NORMAL
   nuc ish 12cen(D12Z3x2) [100]

TP53: NORMAL
   nuc ish 17p13.1(TP53x2) [100]

This analysis is limited to abnormalities detectable by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

**REFERENCES:**

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
LCLS Specimen Number: 238-225-9016-0  
Account Number: 9000999  

Patient Name: SAMPLE REPORT, 510340  
Ordering Physician:  

Date of Birth: 12/01/1987  
Specimen Type: BLOOD  

Gender: F  
Client Reference:  

Patient ID:  
Date Collected: 08/25/2016  

Lab Number: YU16-67603 F  
Date Received: 08/26/2016  

M. Katharine Rudd, PhD, FACMG  
Board Certified Cytogeneticist  

Arundhati Chatterjee, MD  
Medical Director  

Peter Papenhausen, PhD  
National Director of Cytogenetics  

Technical component performed by Laboratory Corporation of America Holdings,  
1904 TW Alexander Drive, RTP, NC, 27709-0153  
(800) 345-4363  

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD.  

Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.  

This document contains private and confidential health information protected by state and federal law.